Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 22, 2008

Simcere Buys 70% Stake in Wuhu Zhong Ren Pharmaceutical for $9.27M

  • Simcere Pharmaceutical plans to acquire a 70% equity interest in Wuhu Zhong Ren Pharmaceutical for RMB 64.82 million, or about $9.27 million. Simcere says that the transaction strengthens its focus on first-to-market branded generic and innovative new drugs as well as expands its anticancer portfolio.

    Zhong Ren Pharmaceutical is a Chinese drug manufacturer specializing in the production of sustained-release antitumor implants. Its key product is SinoFuan, which is reportedly the only sustained-release antitumor implant approved by the State Food and Drug Administration. It is used to treat cancers of the digestive tract.

    Simcere will leverage its marketing channels to distribute SinoFuan. Currently, the firm manufacturers Endu for stage III/IV non-small-cell lung cancer in China.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »